{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T23:52:29Z","timestamp":1775087549930,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Celgene\/BMS"},{"name":"Research Funding (to institution): Incyte, Innocare, Novartis, Genentech Advisory board (to institution): Eli Lilly"},{"name":"Research Funding: Bristol Myer Squibb (BMS), Seattle Genetics, Takeda, Al Therapeutics, Regeneron, Affimed, Trillium, ADC therapeutics"},{"name":"Consultancy: Celgene, MorphoSys, Abbvie, Incyte, Spectrum Research funding: Celgene, Acerta, Karyopharm Therapeutics, Immune Design"},{"name":"Consultancy: Celgene\/BMS, MorphoSys, Ryvu, Kite, Kymera, Curis, Seattle Genetics Research Funding:Celgene\/BMS, MorphoSys, Nanostring"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from follicular lymphoma (FL) is often excluded from clinical trials. Lenalidomide has response rates of 45% in relapsed transformed DLBCL. Herein we present an analysis of MC078E, a phase II clinical trial testing lenalidomide plus R-CHOP (R2CHOP) for patients with untreated transformed\/concurrent DLBCL (NCT00670358). Adult patients with transformed or concurrent DLBCL were included. Patients received six cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) with lenalidomide 25\u2009mg days 1\u201310 of each cycle. The primary outcome was progression-free survival (PFS) at 24 months. Secondary outcomes were response rates, event-free survival (EFS), and overall survival (OS). Thirty-nine patients were accrued from August 5, 2013 to July 28, 2020 and 33 were eligible by central pathology review. The median age was 64 (24\u201380) years, 18 (54%) were male, 25 (76%) were concurrent and 8 (24%) were transformed DLBCL. The PFS, EFS, and OS rates at 24 months were 84.4% (CI<jats:sub>95<\/jats:sub>: 67.2\u201394.7%), 84.5% (CI<jats:sub>95<\/jats:sub>: 72.9\u201398%), and 97.0% (CI<jats:sub>95<\/jats:sub>: 91.3\u2013100%), respectively. R2CHOP is effective in concurrent and transformed DLBCL. The study supports the inclusion of anthracycline-naive transformed and concurrent DLBCL in future clinical trials of novel immunomodulatory analogues.<\/jats:p>","DOI":"10.1038\/s41408-021-00542-z","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T09:03:03Z","timestamp":1632560583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7892-2625","authenticated-orcid":false,"given":"Sanjal H.","family":"Desai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betsy","family":"LaPlant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Macon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca L.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Inwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F.","family":"Porrata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-6758","authenticated-orcid":false,"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-9393","authenticated-orcid":false,"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"key":"542_CR1","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1200\/JCO.1995.13.7.1726","volume":"13","author":"AR Yuen","year":"1995","unstructured":"Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol. 1995;13:1726\u201333.","journal-title":"J Clin Oncol"},{"key":"542_CR2","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","volume":"22","author":"R Advani","year":"2004","unstructured":"Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin\u2019s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454\u20139.","journal-title":"J Clin Oncol"},{"key":"542_CR3","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","volume":"26","author":"AJ Al-Tourah","year":"2008","unstructured":"Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26:5165\u20139.","journal-title":"J Clin Oncol"},{"key":"542_CR4","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1200\/JCO.1997.15.8.2945","volume":"15","author":"Y Bastion","year":"1997","unstructured":"Bastion Y, Blay JY, Divine M, Brice P, Bordessoule D, Sebban C, et al. Elderly patients with aggressive non-Hodgkin\u2019s lymphoma: disease presentation, response to treatment, and survival-a Groupe d\u2019Etude des Lymphomes de l\u2019Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15:2945\u201353.","journal-title":"J Clin Oncol"},{"key":"542_CR5","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","volume":"31","author":"BK Link","year":"2013","unstructured":"Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31:3272\u20138.","journal-title":"J Clin Oncol"},{"key":"542_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","volume":"126","author":"ND Wagner-Johnston","year":"2015","unstructured":"Wagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015;126:851\u20137.","journal-title":"Blood."},{"key":"542_CR7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bjh.14831","volume":"178","author":"S Alonso-\u00c1lvarez","year":"2017","unstructured":"Alonso-\u00c1lvarez S, Magnano L, Alcoceba M, Andrade-Campos M, Espinosa-Lara N, Rodr\u00edguez G, et al. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br J Haematol. 2017;178:699\u2013708.","journal-title":"Br J Haematol"},{"key":"542_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/annonc\/mdu537","volume":"26","author":"C Madsen","year":"2015","unstructured":"Madsen C, Pedersen MB, Vase M\u00d8, Bendix K, M\u00f8ller MB, Johansen P, et al. Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation. Ann Oncol. 2015;26:393\u20139.","journal-title":"Ann Oncol"},{"key":"542_CR9","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1182\/blood.2019000858","volume":"134","author":"Y Wang","year":"2019","unstructured":"Wang Y, Link BK, Witzig TE, Maurer MJ, Allmer C, King RL, et al. Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood. 2019;134:1289\u201397.","journal-title":"Blood."},{"key":"542_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014;343:301\u20135.","journal-title":"Science"},{"key":"542_CR11","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood-2014-11-567792","volume":"125","author":"A Kritharis","year":"2015","unstructured":"Kritharis A, Coyle M, Sharma J, Evens AM. Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood. 2015;125:2471\u20136.","journal-title":"Blood."},{"key":"542_CR12","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","volume":"26","author":"PH Wiernik","year":"2008","unstructured":"Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26:4952\u20137.","journal-title":"J Clin Oncol"},{"key":"542_CR13","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma. Ann Oncol. 2011;22:1622\u20137.","journal-title":"Ann Oncol"},{"key":"542_CR14","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","volume":"57","author":"D Zhu","year":"2008","unstructured":"Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008;57:1849\u201359.","journal-title":"Cancer Immunol Immunother"},{"key":"542_CR15","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","volume":"14","author":"L Wu","year":"2008","unstructured":"Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14:4650\u20137.","journal-title":"Clin Cancer Res"},{"key":"542_CR16","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/leu.2013.95","volume":"27","author":"M Wang","year":"2013","unstructured":"Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27:1902\u20139.","journal-title":"Leukemia."},{"key":"542_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","volume":"33","author":"GS Nowakowski","year":"2015","unstructured":"Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2015;33:251\u20137.","journal-title":"J Clin Oncol"},{"key":"542_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"542_CR19","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood."},{"key":"542_CR20","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Geneva, Switzerland: WHO Press; 2008."},{"key":"542_CR21","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","volume":"31","author":"BK Link","year":"2013","unstructured":"Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31:3272\u20138.","journal-title":"J Clin Oncol"},{"key":"542_CR22","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.20.01375","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Hong F, Scott DW, Macon WR, King RL, Habermann TM, et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized Phase II US Intergroup Study ECOG-ACRIN E1412. J Clin Oncol. 2021;39:1329\u201338.","journal-title":"J Clin Oncol"},{"key":"542_CR23","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, et al. ROBUST: a Phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-Cell lymphoma. J Clin Oncol. 2021;39:1317\u20131328. JCO.20.01366","journal-title":"J Clin Oncol"},{"key":"542_CR24","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1200\/JCO.20.03531","volume":"39","author":"AJ Davies","year":"2021","unstructured":"Davies AJ. Precision medicine in DLBCL: are we there yet? J Clin Oncol. 2021;39:1314\u20131316.","journal-title":"J Clin Oncol"},{"key":"542_CR25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","volume":"21","author":"Y Yang","year":"2012","unstructured":"Yang Y, Shaffer AL, Emre NC, Ceribelli M, Zhang M, Wright G, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21:723\u201337.","journal-title":"Cancer Cell"},{"key":"542_CR26","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1002\/cncr.26135","volume":"117","author":"FJ Hernandez-Ilizaliturri","year":"2011","unstructured":"Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, et al. Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117:5058\u201366.","journal-title":"Cancer."},{"key":"542_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.hoc.2016.07.001","volume":"30","author":"P Sujobert","year":"2016","unstructured":"Sujobert P, Salles G, Bachy E. Molecular classification of diffuse large B-cell lymphoma: what is clinically relevant? Hematol Oncol Clin North Am. 2016;30:1163\u201377.","journal-title":"Hematol Oncol Clin North Am"},{"key":"542_CR28","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, et al. AUGMENT: a Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37:1188\u201399.","journal-title":"J Clin Oncol"},{"key":"542_CR29","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N. Engl J Med. 2018;379:934\u201347.","journal-title":"N. Engl J Med"},{"key":"542_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjh.12570","volume":"163","author":"M Ban-Hoefen","year":"2013","unstructured":"Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, et al. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol. 2013;163:487\u201395.","journal-title":"Br J Haematol"},{"key":"542_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/hon.2601","volume":"37","author":"M M\u00e9ndez","year":"2019","unstructured":"M\u00e9ndez M, Torrente M, S\u00e1nchez-Beato M, Gonz\u00e1lez-Rinc\u00f3n J, Royuela A, G\u00f3mez-Codina J, et al. Transformed follicular lymphoma in the rituximab era: a report from the Spanish Lymphoma Oncology Group. Hematol Oncol. 2019;37:143\u201350.","journal-title":"Hematol Oncol"},{"key":"542_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood.2019000258","volume":"134","author":"CL Freeman","year":"2019","unstructured":"Freeman CL, Kridel R, Moccia AA, Savage KJ, Villa DR, Scott DW, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019;134:761\u20134.","journal-title":"Blood."},{"key":"542_CR33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1182\/hematology.2020000115","volume":"2020","author":"S Smith","year":"2020","unstructured":"Smith S. Transformed lymphoma: what should I do now? Hematology. 2020;2020:306\u201311.","journal-title":"Hematology."},{"key":"542_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/blood-2020-140607","volume":"136","author":"SH Desai","year":"2020","unstructured":"Desai SH, Chaturvedi M, Hameed R, Baez Sosa V, Shenoy A. DA-EPOCH-R has comparable outcomes in de novo and transformed diffuse large B cell lymphoma. Blood. 2020;136:15\u20136.","journal-title":"Blood."},{"key":"542_CR35","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, Tournilhac O, Jurczak W, Liberati AM, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21:978\u201388.","journal-title":"Lancet Oncol"},{"key":"542_CR36","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1200\/JCO.2020.38.15_suppl.8020","volume":"38","author":"GS Nowakowski","year":"2020","unstructured":"Nowakowski GS, Rodgers TD, Marino D, Frezzato M, Barbui AM, Castellino C, et al. RE-MIND study: a propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2020;38:8020.","journal-title":"J Clin Oncol"},{"key":"542_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/1078-0432.CCR-18-1203","volume":"25","author":"DW Rasco","year":"2019","unstructured":"Rasco DW, Papadopoulos KP, Pourdehnad M, Gandhi AK, Hagner PR, Li Y, et al. A first-in-human study of novel cereblon modulator avadomide (CC-122) in advanced malignancies. Clin Cancer Res. 2019;25:90\u20138.","journal-title":"Clin Cancer Res"},{"key":"542_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2020-136295","volume":"136","author":"TJ Phillips","year":"2020","unstructured":"Phillips TJ, Olszewski AJ, Munoz J, Kim TM, Yoon DH, Greil R, et al. Mosunetuzumab, a novel CD20\/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma. Blood. 2020;136:37\u20138.","journal-title":"Blood."},{"key":"542_CR39","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1182\/blood-2019-122451","volume":"134","author":"R Bannerji","year":"2019","unstructured":"Bannerji R, Allan JN, Arnason JE, Brown JR, Advani RH, Barnes JA, et al. Clinical activity of REGN1979, a bispecific human, anti-CD20 \u00d7 anti-CD3 antibody, in patients with relapsed\/refractory (R\/R) B-cell non-hodgkin lymphoma (B-NHL). Blood. 2019;134:762.","journal-title":"Blood."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00542-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00542-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00542-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:23:32Z","timestamp":1669919012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00542-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["542"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00542-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]},"assertion":[{"value":"10 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yucai Wang: research funding from Incyte, Innocare, Novartis, Genentech and member of the advisory board of Eli Lilly; Stephen M. Ansell: research funding from Bristol Myer Squibb (BMS), Seattle Genetics, Takeda, Al Therapeutics, Regeneron, Affimed, Trillium, ADC therapeutics; Thomas E. Witzig: consultancy in Celgene, MorphoSys, Abbvie, Incyte, Spectrum, and research funding: Celgene, Acerta, Karyopharm Therapeutics, Immune Design; Grzegorz S. Nowakowski: consultancy in Celgene\/BMS, MorphoSys, Ryvu, Kite, Kymera, Curis, Seattle Genetics and research funding from Celgene\/BMS, MorphoSys, Nanostring; Rebecca L. King: research funding from BMS\/Celgene. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"160"}}